Drugs / FMP1
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00308061 | Jul 2003 → Sep 2004 | malaria | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 1 | NCT00317473 | Jun 2003 → Jul 2004 | Plasmodium falciparum malaria | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01556945 | Apr 2001 → Feb 2002 | Plasmodium falciparum malaria | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FMP1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01556945 ↗ |
| Known as | Falciparum Merozoite Protein-1 | “The final product, designated Falciparum Merozoite Protein-1 (FMP1), had endotoxin levels significantly lower than FDA standards.” PMID 12742586 ↗ May 2003 |
| Modality | Protein / enzyme biologic | “FMP1 antigen contained 62.5 ug of lyophilized protein” NCT00308061 ↗ |
| Route | Intramuscular | “500 uL of FMP1/AS02A is given to subject on days 0, 30+7, and 60+7 in the left deltoid muscle” NCT00308061 ↗ |